Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
0.3640
Dollar change
+0.0172
Percentage change
4.96
%
Index- P/E- EPS (ttm)-1.65 Insider Own1.56% Shs Outstand3.33M Perf Week-1.16%
Market Cap1.21M Forward P/E- EPS next Y- Insider Trans152.27% Shs Float3.28M Perf Month-13.33%
Income-6.35M PEG- EPS next Q- Inst Own24.16% Short Float1.74% Perf Quarter-7.14%
Sales5.49M P/S0.22 EPS this Y- Inst Trans13.34% Short Ratio0.34 Perf Half Y-48.73%
Book/sh2.25 P/B0.16 EPS next Y- ROA-39.48% Short Interest0.06M Perf Year-68.35%
Cash/sh2.88 P/C0.13 EPS next 5Y- ROE-46.86% 52W Range0.29 - 2.08 Perf YTD-12.50%
Dividend Est.- P/FCF- EPS past 5Y39.17% ROI-46.79% 52W High-82.50% Beta0.45
Dividend TTM- Quick Ratio6.58 Sales past 5Y55.92% Gross Margin27.58% 52W Low24.96% ATR (14)0.04
Dividend Ex-Date- Current Ratio7.03 EPS Y/Y TTM99.47% Oper. Margin-127.48% RSI (14)49.84 Volatility8.85% 11.74%
Employees13 Debt/Eq0.09 Sales Y/Y TTM239.77% Profit Margin-115.75% Recom3.00 Target Price20.00
Option/ShortNo / Yes LT Debt/Eq0.06 EPS Q/Q79.70% Payout- Rel Volume0.35 Prev Close0.35
Sales Surprise10.04% EPS Surprise- Sales Q/Q163.99% EarningsFeb 13 BMO Avg Volume168.92K Price0.36
SMA20-0.01% SMA50-0.10% SMA200-41.95% Trades Volume59,806 Change4.96%
Mar-20-24 08:30AM
Feb-13-24 05:41PM
Feb-09-24 08:00AM
Jan-18-24 04:41PM
Jan-16-24 08:00AM
06:03PM Loading…
Dec-19-23 06:03PM
Nov-29-23 08:00AM
Nov-14-23 08:04AM
Nov-02-23 08:00AM
Oct-26-23 07:15PM
Oct-25-23 09:00AM
Oct-24-23 04:38PM
07:30AM
Sep-29-23 01:21PM
Sep-22-23 06:15PM
08:30AM Loading…
Sep-07-23 08:30AM
Jul-21-23 07:30AM
Jul-20-23 07:30AM
Jun-22-23 02:28PM
07:30AM
Jun-01-23 07:30AM
May-24-23 06:51PM
May-18-23 05:00PM
May-15-23 12:33PM
Mar-28-23 07:30AM
Mar-13-23 07:30AM
Mar-10-23 08:35AM
Mar-07-23 08:35AM
07:00AM
Mar-06-23 06:00PM
05:00PM Loading…
Feb-17-23 05:00PM
Feb-09-23 09:41PM
Jan-10-23 07:30AM
Dec-15-22 06:17PM
Dec-12-22 06:47PM
Nov-23-22 12:18PM
Nov-21-22 05:00PM
Nov-18-22 08:00AM
Nov-17-22 10:32AM
07:30AM
Nov-16-22 12:13PM
07:00AM
Nov-11-22 06:51PM
Nov-10-22 07:30AM
Oct-26-22 07:30AM
Oct-24-22 10:13AM
Sep-23-22 12:29PM
Sep-19-22 06:00PM
Sep-13-22 05:12PM
Sep-09-22 05:00PM
Sep-08-22 02:08PM
Aug-23-22 05:00PM
Aug-09-22 07:30AM
Jul-25-22 07:30AM
Jul-18-22 07:30AM
Jul-12-22 11:33PM
Jun-14-22 07:30AM
Jun-09-22 07:30AM
Jun-06-22 06:49PM
Jun-02-22 08:00AM
May-13-22 08:45AM
07:30AM
May-05-22 07:30AM
May-03-22 12:00PM
Apr-28-22 07:30AM
Apr-21-22 07:30AM
Apr-19-22 07:30AM
Mar-17-22 07:30AM
Mar-08-22 07:30AM
Feb-16-22 07:30AM
Feb-15-22 07:30AM
Feb-14-22 08:45PM
07:34PM
Feb-10-22 07:30AM
Jan-19-22 07:30AM
Jan-05-22 07:30AM
Dec-30-21 07:30AM
Dec-20-21 07:30AM
Dec-17-21 07:57PM
Nov-23-21 07:30AM
Nov-18-21 12:23PM
Nov-17-21 08:25AM
Nov-10-21 09:05AM
07:30AM
Nov-03-21 07:30AM
Oct-22-21 12:48PM
07:32AM
Oct-18-21 07:02AM
Oct-15-21 11:14AM
Oct-13-21 04:30PM
Sep-30-21 08:46AM
07:30AM
Sep-24-21 12:31PM
07:30AM
Sep-20-21 07:50AM
Sep-17-21 01:14PM
07:30AM
Sep-13-21 11:47AM
09:59AM
08:43AM
InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. It is also involved in cannabinoid-based therapies and a biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. It operates through the InMed and BayMedica segments. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HULL ANDREWDirectorFeb 21 '24Buy0.3937,50014,62538,258Feb 22 01:38 PM
ADAMS ERIC APresident & CEOFeb 20 '24Buy0.3641,60014,92243,959Feb 21 02:58 PM